novo nordisk glp-1 receptor agonist weight management diabetes treatments In the original clinical trials looking at semaglutide (the in Nordisk's Ozempic and Wegovy) and tirzepatide (in Eli Lilly's Mounjaro and Zepbound), patients gained back most of the after GLP-1 obesity drugs cleared of

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

this study examined this relationship

Updated searches were run on October 4, 2023, March 20, 2024, and May 29, 2024

10.1556/650.2019.31615 129 WolffenbuttelB

5 Saxenda (liraglutide) is injected subcutaneously (under the skin) usually once daily, with or without meals

The most common side effects of tirzepatide are gastrointestinal: Nausea: Reported by 12-33% of participants depending on dose (most common early in treatment) Diarrhea: 12-21% of participants Constipation: 6-11% of participants Vomiting: 5-13% of participants Decreased appetite: Expected therapeutic effect but can be uncomfortable These side effects are typically most intense during the first few weeks at each new dose level and tend to improve as the body adjusts